- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06083402
Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women
October 11, 2023 updated by: Natals, Inc. dba Ritual
Evaluating the Efficacy of a Dietary Supplement on Parameters of Skin Aging: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
As the body ages, the skin experiences natural changes in structure and composition.
These changes may manifest visibly as increased skin dryness, wrinkling, and a loss of firmness/elasticity.
In this double-blind, randomized, placebo-controlled trial, the investigators will recruit healthy men and women with mild to moderate signs of skin aging and randomly assign them to either receive a HyaCera™ or placebo for 12 weeks.
The investigators will perform a series of objective and subjective measurements to assess changes in skin condition.
The investigators hypothesize that consumption of HyaCera™ leads to improvements in the general condition of the skin including skin hydration, crow's feet wrinkling, and other skin aging parameters.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Raritan, New Jersey, United States, 08869
- Princeton Consumer Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male and female volunteers, 25 - 70 years old with mild to moderate fine lines and wrinkles
- All ethnicities and skin types
- Willing to maintain current skincare regimen on face, arms, and legs and withhold all facial and body treatments throughout the course of the study
Exclusion Criteria:
- Self-reported pregnant or breastfeeding or planning to become pregnant during the course of the study
- Any conditions on the face, arms and legs that would interfere with evaluations
- Under treatment for any known health issues/medical conditions including chronic health conditions and skin diseases/conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active
Participants receive 1 HyaCera™ capsule orally once daily for 12 weeks
|
1 Ritual HyaCera capsule once daily
|
Placebo Comparator: Placebo
Participants receive 1 placebo capsule orally once daily for 12 weeks
|
1 placebo capsule once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Crow's Feet Wrinkles
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Degree of crow's feet wrinkling will be measured via Visioscan®
|
at week 0, Week 4, Week 8, and Week 12
|
Skin Smoothness
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Skin smoothness will be measured via Visioscan®
|
at week 0, Week 4, Week 8, and Week 12
|
Skin Hydration
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Skin surface hydration will be measured via Corneometer® 825
|
at week 0, Week 4, Week 8, and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Elasticity
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Skin elasticity will be measured via Cutometer® MPA 580
|
at week 0, Week 4, Week 8, and Week 12
|
Skin Barrier Function
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Skin barrier function (as transepidermal water loss) will be measured via Tewameter®
|
at week 0, Week 4, Week 8, and Week 12
|
Skin Scaliness
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Skin scaliness will be measured via Visioscan®
|
at week 0, Week 4, Week 8, and Week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dermatologist grading of skin condition
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Visual and tactile dermatologist evaluation of skin condition (fine lines in the crow's feet area, wrinkles in the crow's feet area, skin dryness, skin radiance, and skin smoothness) based on 10-point grading scale (with 0 being no signs of aging and 9 being the most severe)
|
at week 0, Week 4, Week 8, and Week 12
|
Self-evaluation of perceived changes in skin condition
Time Frame: at week 0, Week 4, Week 8, and Week 12
|
Self-evaluation of changes in skin condition and signs of skin aging (i.e.
fine lines & wrinkles, skin texture, skin smoothness, skin plumpness, skin glow/radiance, skin hydration, skin elasticity, skin redness, skin itchiness) using a 5-point Likert scale (options: much worse, somewhat worse, stayed the same, somewhat better, much better)
|
at week 0, Week 4, Week 8, and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 12, 2023
Primary Completion (Actual)
October 6, 2023
Study Completion (Actual)
October 6, 2023
Study Registration Dates
First Submitted
August 16, 2023
First Submitted That Met QC Criteria
October 11, 2023
First Posted (Actual)
October 16, 2023
Study Record Updates
Last Update Posted (Actual)
October 16, 2023
Last Update Submitted That Met QC Criteria
October 11, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HyaCera2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Aging
-
Amazentis SAproDERM GmbHCompleted
-
Endymion Medical LtdCompleted
-
BioibericaRecruiting
-
Crown Laboratories, Inc.Completed
-
HugelCompletedSkin AgingKorea, Republic of
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació... and other collaboratorsCompleted
-
Medy-ToxCompletedSkin AgingKorea, Republic of
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Revance Therapeutics, Inc.Completed
-
Revance Therapeutics, Inc.CompletedSkin AgingUnited States
Clinical Trials on HyaCera™
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bKorea, Republic of
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis AGermany, Belgium, Czechia
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularActive, not recruitingAortic AneurysmGermany, New Zealand, United States, Netherlands, Switzerland, United Kingdom, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
Boston Scientific CorporationCompletedTransient Ischemic Attack | Thromboembolic Stroke | Stroke PreventionUnited States, Argentina, Germany